• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by OS Therapies Incorporated

    7/15/26 7:36:48 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

    FORM D

    Notice of Exempt Offering of Securities
    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001795091
    OS THERAPIES Inc
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    OS Therapies Inc
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    OS Therapies Inc
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Grasonville MARYLAND 21638 410-297-7793

    3. Related Persons

    Last Name First Name Middle Name
    Romness Paul A.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Chairman, President and Chief Executive Officer
    Last Name First Name Middle Name
    Petit Robert G.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Medical Officer and Chief Scientific Officer
    Last Name First Name Middle Name
    Acevedo Christopher P.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    Ciccio John
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    McKean Dieser Avril
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Eagle Craig
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Jarry Olivier
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Search Theodore F.
    Street Address 1 Street Address 2
    115 Pullman Crossing Road Suite 103
    City State/Province/Country ZIP/PostalCode
    Grasonville MARYLAND 21638
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2026-06-30    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
    X Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $9,250,000 USD
    or    Indefinite
    Total Amount Sold $1,600,000 USD
    Total Remaining to be Sold $7,650,000 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    OS Therapies Inc /s/ Christopher P. Acevedo Christopher P. Acevedo Chief Financial Officer 2026-07-15

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $OSTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    7/9/2026$7.00Buy
    Roth Capital
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on OS Therapies with a new price target

    Roth Capital initiated coverage of OS Therapies with a rating of Buy and set a new price target of $7.00

    7/9/26 9:30:08 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on OS Therapies with a new price target

    Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

    4/2/25 8:01:55 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    SEC Filings

    View All

    SEC Form D filed by OS Therapies Incorporated

    D - OS Therapies Inc (0001795091) (Filer)

    7/15/26 7:36:48 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: OS Therapies Incorporated filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - OS Therapies Inc (0001795091) (Filer)

    7/7/26 9:18:33 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - OS Therapies Inc (0001795091) (Filer)

    7/2/26 4:30:21 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

    CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical Methods MeetingNew York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from the U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) to review the Company's pharmacodynamic response biomarker data (the "OST-HER2 Biomarker Data") – patent pending. CDER's Biomarkers, EndpointS, and other Tools (BEST) resources is part of its Biomarker Qualifica

    7/8/26 9:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Third Quarter 2026 Corporate Outlook

    Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market accessNew York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on upcoming clinical and regulatory milestones for the Company's lead program OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteos

    7/6/26 9:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Appoints Dr. Craig Eagle to Board of Directors

    Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has appointed Dr. Craig Eagle to the Company's Board of Directors. Dr. Eagle currently serves as the Company's Chief Medical Advisor. The Company also thanks Karim Galzahr for his service to the Board of Directors and will continue as a member of the Company's advisory board."Having enjoyed participating in recent U.S., European and U.K. regulatory meetings as we prepare for

    7/2/26 7:30:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 5 filed by Romness Paul A.

    5/A - OS Therapies Inc (0001795091) (Issuer)

    5/15/26 6:30:02 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mckean-Dieser Avril Suzette

    4 - OS Therapies Inc (0001795091) (Issuer)

    2/13/26 4:43:41 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Search Theodore F.

    4 - OS Therapies Inc (0001795091) (Issuer)

    2/13/26 4:43:05 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Leadership Updates

    Live Leadership Updates

    View All

    $OSTX
    Financials

    Live finance-specific insights

    View All

    OS Therapies Appoints Dr. Craig Eagle to Board of Directors

    Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has appointed Dr. Craig Eagle to the Company's Board of Directors. Dr. Eagle currently serves as the Company's Chief Medical Advisor. The Company also thanks Karim Galzahr for his service to the Board of Directors and will continue as a member of the Company's advisory board."Having enjoyed participating in recent U.S., European and U.K. regulatory meetings as we prepare for

    7/2/26 7:30:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor

    Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2 approval decisions expected by year-end 2026Upcoming FDA Pre-BLA meeting will focus on the use of recent seroconversion biomarker data as a key surrogate clinical efficacy endpoint to support a BLA for OST-HER2 under the Accelerated Approval ProgramCommercialization and reimbursement preparations well underway for the U.S., U.K., and Europe in parallel with ongoing partnership discussionsNew York, New York and Rockville, Maryland--(Newsfile Corp. - May 14, 2026) - OS Therapies, Inc. (NY

    5/14/26 7:30:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

    Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeria oncology pipeline prioritization, combinations with other oncology-focused biotechnologies and tADC candidate selection for further developmentNew York, New York--(Newsfile Corp. - April 13, 2026) - OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, announced today that Dr. Robert "Bob" S. Langer, co-founder of Moderna, was appointed to the Company's strategic advisory board. Dr. Langer will assist managemen

    4/13/26 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

    Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the OST-HER2 approach. Participants will include strategic advisors Dr. Craig Eagle and Dr. Bob Langer, and Osteosarcoma key opinion leader Dr. Peter Anderson from Cleveland Clinic.EMA and Australia TGA (ATGA) align on 3-year overall survival as the approvable clinical efficacy endpoint for Conditional Marketing Authorizations (CMAs), with alignment also achieved on confirmatory Phase 3 initiation, initially only in Australia, planned for Q3 2026 to meet regulatory requirement to support early a

    4/30/26 6:00:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

    Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meetings with EU EMA and Australian TGANew York, New York--(Newsfile Corp. - April 27, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced that it will be hosting a conference call on Thursday April 30, 2026 at 8:30am ET to review the data that supported the recent Patent Cooperation Treaty (PCT) international application for a OST-HER2 pharmacodynamic biomarker1 (the "OST-HER2

    4/27/26 4:01:00 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

    New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference call later in April 2026 to review new biomarker signatureBiomarker signature meets pharmacodynamic/response criteria established by FDA's Biomarkers, EndpointS and other Tools (BEST) program for use as a surrogate clinical endpoint of 1-year event free survival and 2-year overall survival in OST-HER2's Phase 2b trial in the prevention of delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma to support a BLA submission under FDA's Accelerated Approval ProgramNew York, New York--(New

    4/16/26 7:20:00 AM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OS Therapies Incorporated

    SC 13G - OS Therapies Inc (0001795091) (Subject)

    8/28/24 4:30:09 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care